Atea Pharmaceuticals, Inc.

NASDAQ•AVIR

CEO: Dr. Jean-Pierre Sommadossi Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2020-10-30

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Contact Information

225 Franklin Street, Suite 2100, Boston, MA, 02110, United States

857-284-8891

ateapharma.com

Market Cap

$476.57M

P/E (TTM)

-3.0

17.9

Dividend Yield

52W High

$6.45

52W Low

$2.46

52W Range

91%

Rank45Top 56.8%

3.6

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Weak • 3.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.57+0.00%

4-Quarter Trend

FCF

-$28.22M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

HCV Phase 3 Trials Progressing C-BEYOND fully enrolled; C-FORWARD enrollment expected complete YE 2026; NDA targeted March 2027.

Net Loss Narrows Significantly Net loss decreased $10.0 M to $(158.3) M in 2025; R&D spend increased slightly to $148.0 M.

Cash Position Strong Cash, equivalents, and securities totaled $301.8 M on December 31, 2025, sufficient through 2027.

Workforce Reduction Completed 25% workforce reduction in Q1 2025 expected to yield $15.0 M aggregate cost savings through 2027.

Risk Factors

High Dependence on HCV Candidate Business highly dependent on successful HCV regimen development, approval, and commercialization; failure causes significant harm.

Need Substantial Future Financing Expect substantial operating expenses; failure to obtain necessary capital could delay or terminate product development efforts.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, expensive, and inherently unpredictable; failure to obtain approval seriously harms business.

Intellectual Property Litigation Risk Facing patent challenges from Gilead Sciences regarding bemnifosbuvir; adverse ruling requires licensing or halts commercialization.

Outlook

Targeting HCV NDA Submission Targeting submission of HCV regimen NDA to FDA in March 2027, pending successful completion of Phase 3 trials.

Initiate HEV Phase 1 Study Anticipate initiating clinical development of AT-587 for chronic HEV with a first-in-human Phase 1 study mid-2026.

Cash Funds Operations Through 2027 Current cash position of $301.8 M is expected to fund planned operations through the end of 2027.

Merck Milestone Payment Anticipated Next $10.0 M Merck milestone payment anticipated due upon acceptance of HCV regimen NDA in H1 2027.

Peer Comparison

Revenue (TTM)

VNDA

$216.11M

+8.7%

ARCT

$74.12M

-46.4%

ENTA

$66.98M

+0.6%

Gross Margin (Latest Quarter)

ENTA

100.0%

+0.0pp

PRQR

100.0%

+0.0pp

VNDA

93.3%

+0.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
VTYX	$1.00B	-9.4	-48.1%	4.7%
OMER	$793.38M	-6.1	57.3%	103.2%
ALLO	$539.35M	-2.8	-57.1%	18.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 11, 2026

EPS:-$0.56

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data